Skip to main content

AstraZeneca Plc Value Stock - Dividend - Research Selection

AstraZeneca Plc

ISIN: GB0009895292, WKN: 886455

Market price date: 21.05.2021
Market price: 117,00 USD




AstraZeneca Plc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 24-02-2021
Cash flow
Net operating cash flow 4.799.000.000
Capital Expenditures -2.606.000.000
Free cash flow 1.990.000.000
Balance sheet
Total Equity 15.622.000.000
Liabilities & Shareholders equity 66.729.000.000
Income statement
Net income 3.196.000.000
Eps (diluted) 1,040
Diluted shares outstanding 1.313.000.000
Net sales/revenue 26.617.000.000

Fundamental ratios calculated on: 21-05-2021

Ratios
Key figures 21-05-2021
Cash flow
P/C 31,68
   
P/FC 76,41
Balance sheet
ROI4,79
ROE23,41
Income statement
P/E111,35
Div. Yield2,42%
P/B9,73
P/S5,71


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAZNCF
Market Capitalization152.045.404.160,00 USD
Country
IndicesFTSE 100
Sectors
Raw Data SourceIFRS in Millionen USD
Stock Split
Internetwww.astrazeneca.com


Description of the company

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.astrazeneca.com